Finch Therapeutics Group, Inc. (FNCH)

NASDAQ: FNCH · IEX Real-Time Price · USD
8.38 -0.25 (-2.90%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap397.87M
Revenue (ttm)19.53M
Net Income (ttm)-52.20M
Shares Out47.48M
EPS (ttm)-1.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,566
Open8.70
Previous Close8.63
Day's Range8.16 - 8.70
52-Week Range8.16 - 22.50
Betan/a
AnalystsStrong Buy
Price Target30.00 (+258.0%)
Earnings Daten/a

About FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of ...

IndustryBiotechnology
IPO DateMar 19, 2021
Employees191
Stock ExchangeNASDAQ
Ticker SymbolFNCH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for FNCH stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 258.00% from the latest price.

Price Target
$30.00
(258.00% upside)
Analyst Consensus: Strong Buy

News

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigati...

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 weeks ago - GlobeNewsWire

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

1 month ago - GlobeNewsWire

Finch Therapeutics' C. Difficile Infection Candidate Meets Primary Goal In Mid-Stage Study

Finch Therapeutics Group Inc (NASDAQ: FNCH) announced positive topline results from PRISM-EXT, an open-label extension of the PRISM3 Phase 2 trial evaluating CP101 to prevent recurrent C. difficile infe...

2 months ago - Benzinga

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 months ago - GlobeNewsWire

Finch Therapeutics Announces Transition of Chief Medical Officer

SOMERVILLE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 months ago - GlobeNewsWire

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurre...

SOMERVILLE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 months ago - GlobeNewsWire

Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American ...

SOMERVILLE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

2 months ago - GlobeNewsWire

Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

3 months ago - GlobeNewsWire

Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors

SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

3 months ago - GlobeNewsWire

Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

4 months ago - GlobeNewsWire

Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

5 months ago - GlobeNewsWire

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program

SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

5 months ago - GlobeNewsWire

Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes

SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Huma...

6 months ago - GlobeNewsWire

Finch Therapeutics to Present at Upcoming Virtual Investor Conferences

SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

7 months ago - GlobeNewsWire

Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or the “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First ...

8 months ago - GlobeNewsWire

Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference

SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

8 months ago - GlobeNewsWire

Finch Therapeutics Appoints Susan E. Graf to Board of Directors

SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

8 months ago - GlobeNewsWire

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

9 months ago - Benzinga

Finch Therapeutics Announces Pricing of Upsized Initial Public Offering

SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

10 months ago - GlobeNewsWire